Quest Diagnostics Inc. on Thursday warned that demand for COVID-19 molecular testing will slow down through the end of 2021 as infections decline, but a recovery in its core testing business will likely cushion the blow.
Shares of the U.S. laboratory reversed course and fell 3.5 percent to $141.75 in early trading after it said it expects to record about 50,000 molecular tests per day in the fourth quarter. The company averaged 83,000 tests a day in the third quarter.
